Literature DB >> 390098

Creutzfeldt-Jakob disease treated with amantadine.

W L Sanders.   

Abstract

A case of Creutzfeldt-Jakob disease treated with amantadine showed considerable initial improvement, followed by a period of almost five years during which the patient remained in a relatively stable condition until he died accidentally. The diagnosis was confirmed histologically.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 390098      PMCID： PMC490372          DOI： 10.1136/jnnp.42.10.960

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  3 in total

1.  Epidemiology of Creutzfeldt-Jakob disease in England and Wales.

Authors:  W B Matthews
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-03       Impact factor: 10.154

2.  Creutzfeldt-Jakob disease treated with amantidine. A report of two cases.

Authors:  W L Sanders; T L Dunn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-08       Impact factor: 10.154

3.  Transmission, from man to hamster, of Creutzfeldt-Jakob disease with clinical recovery.

Authors:  E E Manuelidis; L Manuelidis; J H Pincus; W F Collins
Journal:  Lancet       Date:  1978-07-01       Impact factor: 79.321
  3 in total
  7 in total

Review 1.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

2.  A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970-79. I: Clinical features.

Authors:  R G Will; W B Matthews
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-02       Impact factor: 10.154

Review 3.  Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: implications for physicians.

Authors:  C MacKnight; K Rockwood
Journal:  CMAJ       Date:  1996-09-01       Impact factor: 8.262

4.  Antibiotics and antivirals do not modify experimentally-induced Creutzfeldt-Jakob disease in mice.

Authors:  J Tateishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-08       Impact factor: 10.154

5.  The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection.

Authors:  R H Kimberlin; C A Walker
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

Review 6.  Prions and related neurological diseases.

Authors:  M Pocchiari
Journal:  Mol Aspects Med       Date:  1994

Review 7.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.